Programs we won't recommend
We evaluate every US-licensed telehealth weight-loss program we can find. Some we recommend with reservations. Some we exclude entirely. The reasons we exclude them are themselves a buying guide — they describe the anti-patterns that should make any telehealth shopper close the tab.
Supply transparency
Compounded-only platforms without 503A/503B disclosure
If a program sells compounded GLP-1 without naming the dispensing pharmacy or whether it's 503A or 503B registered, the safety story is unverifiable. We exclude these by default.
Financial risk
Programs requiring multi-month prepay before clinical eligibility
Programs that require 3 or 6 months of upfront payment BEFORE the clinical eligibility evaluation transfer eligibility risk to the patient. Mainstream programs determine eligibility first, then bill.
Cancellation
GLP-1 programs with no documented refund window
Without a stated refund window, mid-month cancellation is at the program's discretion. We require an explicit refund policy on the public site.
Clinical accountability
Platforms with no named medical director
A telehealth platform without a publicly named medical director (with credentials and license number verifiable) cannot be evaluated for clinical accountability. State medical boards require accountability; so do we.
Pricing transparency
Programs with hidden membership fees on top of medication cost
Programs that advertise a low medication price but layer a non-refundable monthly membership fee that's only disclosed at checkout fail our pricing-transparency criterion. The total monthly cost must be visible above the fold.
Legal compliance
GLP-1 sellers without state-licensing transparency
Telehealth prescribing requires the prescriber to be licensed in the patient's state. Programs that don't publish which states they operate in and which clinicians cover those states fail compliance basics.
How exclusion works
We do not name specific brands in this list. Naming exposes us to defamation risk without serving the reader. Instead we name the failure pattern. When you encounter a real program that matches a pattern here, that's the buying decision.
If a program corrects the issue (publishes the medical director, drops the prepay requirement, names the compounding pharmacy), we re-evaluate. Reach editorial via the contact page.